Established in 2003, SENSIMED SA is a Swiss company with its principal focus on design, development and commercialization of integrated micro-systems for medical devices. SENSIMED is a spin off from the Ecole Polytechnique Fédérale de Lausanne (EPFL) and grows within a world-leading cluster for medical devices in the lake of Geneva area. SENSIMED has developed and is now selling a patented and breakthrough non-invasive contact lens device with an embedded microprocessor that will significantly improve identification and treatment of glaucoma disease by monitoring intraocular pressure around the clock (SENSIMED Triggerfish®). The initial concept of the gauge on the eye lens and the first developments are arising out of the research group headed by Professor Philippe Renaud (Laboratoire de microsystèmes).

Glaucoma is an asymptomatic, progressive and irreversible disease which leads to blindness unless adequate treatment is provided. Glaucoma is the second most common cause of blindness worldwide and affects about 68 million people. Intraocular pressure is one of known causes of glaucoma. This behaviour is individual, has transient peaks and varies significantly over a 24 hour period. By providing ophthalmologists with the 24-hour profile of fluctuations in intraocular pressure, the SENSIMED Triggerfish® fulfill doctor’s need to better understand the condition of the patient, to provide personalized treatment, and to monitor the efficacy of the treatment over time.